SCHEMBL2507542

SCHEMBL2507542

CC(C)(C)OC(=O)NCc1ccc(C(=O)NN)cc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.60
L3MBTL1 Q9Y468 2/20 0.57
HDAC1 Q13547 3/20 0.57
EPHX2 P34913 7/20 0.51
NR1H4 Q96RI1 5/20 0.51
HDAC6 Q9UBN7 4/20 0.51
HDAC10 Q969S8 1/20 0.51
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
GAA P10253 1/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.49
HDAC3 O15379 1/20 0.49
HDAC8 Q9BY41 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22291745 0.88 EPHX2 (0.64) NAMPTL3MBTL1HDAC1EPHX2NR1H4
SCHEMBL3180689 0.87 L3MBTL1 (0.61) NAMPTL3MBTL1HDAC1HDAC6HDAC10
SCHEMBL6622954 0.87 NAMPT (0.59) NAMPTL3MBTL1HDAC1EPHX2NR1H4
SCHEMBL8220824 0.86 EPHX2 (0.60) NAMPTL3MBTL1HDAC1EPHX2NR1H4
SCHEMBL8338878 0.86 NAMPT (0.56) NAMPTL3MBTL1HDAC1EPHX2NR1H4
SCHEMBL23899245 0.85 NAMPT (0.72) NAMPTL3MBTL1HDAC1EPHX2NR1H4
SCHEMBL2511243 0.85 CA2 (0.55) NAMPTCA1CA2NPC1RAB9A
SCHEMBL5736115 0.85 HDAC1 (0.60) NAMPTL3MBTL1HDAC1EPHX2NR1H4
SCHEMBL23775465 0.85 ALDH1A1 (0.58) NAMPTL3MBTL1HDAC1EPHX2NR1H4
SCHEMBL18295371 0.85 L3MBTL1 (0.54) NAMPTL3MBTL1HDAC1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163049-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS EXELIXIS INC (US) 2025-05-22 US disclosed
EP-4472946-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS Exelixis, Inc. (US) 2024-12-11 EP disclosed
US-12103928-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2024-10-01 US disclosed
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
WO-2023148643-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-08-10 WO disclosed
EP-3328843-B1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2022-10-26 EP disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
CN-108137518-B 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same 株式会社钟根堂 2021-08-31 CN disclosed
WO-2011123678-A2 SUBSTITUTED BENZO-PYRIDO-TRIAZOLO-DIAZEPINE COMPOUNDS ARQULE, INC. (US) 2011-10-06 WO disclosed
WO-2011123678-A2 SUBSTITUTED BENZO-PYRIDO-TRIAZOLO-DIAZEPINE COMPOUNDS ARQULE, INC. (US) 2011-10-06 WO disclosed
US-20110245236-A1 Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds ARQULE, INC. (US) 2011-10-06 US disclosed
US-20110245236-A1 Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds ARQULE, INC. (US) 2011-10-06 US disclosed
US-5981531-A FOR INHIBITING PLATELET AGGREGATION ZENECA LIMITED (GB) 1999-11-09 US disclosed
US-5760057-A ANTICOAGULANTS ZENECA LIMITED (GB) 1998-06-02 US disclosed
EP-0632016-B1 1,2-Diacylated hydrazine derivatives and their use as cell adhesion inhibitors ZENECA LTD (GB) 1997-04-09 EP disclosed
US-5612373-A ANTICOAGULANTS ZENECA LIMITED (GB) 1997-03-18 US disclosed
WO-1995000472-A1 1,2 DIACYLATED HYDRAZINE DERIVATIVES AND THEIR USE AS ALL ADHESION INHIBITORS ZENECA LIMITED (GB) 1995-01-05 WO disclosed
EP-0632016-A1 1,2-Diacylated hydrazine derivatives and their use as cell adhesion inhibitors ZENECA LIMITED (GB) 1995-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 NAMPT 832/4885L3MBTL1 4674/4885HDAC1 2457/4885
US-20110245236-A1 Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds BRD4, PDXK, THPO NAMPT 426/4885L3MBTL1 4506/4885HDAC1 444/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 NAMPT 832/4885L3MBTL1 4674/4885HDAC1 2457/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 NAMPT 832/4885L3MBTL1 4674/4885HDAC1 2457/4885
US-12103928-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 NAMPT 832/4885L3MBTL1 4674/4885HDAC1 2457/4885
US-20250163049-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS USP1, USP2, SUMO1 NAMPT 4125/4885L3MBTL1 1682/4885HDAC1 111/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 NAMPT 832/4885L3MBTL1 4674/4885HDAC1 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.